Associations between novel genetic variants in the promoter region of MALAT1 and risk of colorectal cancer

The metastasis-associated lung adenocarcinoma transcript 1 ( ), a well-known long non-coding RNA, is involved in pathogenesis and progress of multiple tumors. However, no study has been performed to investigate the relationship between the genetic variants in promoter region of and colorectal cancer...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget 2017-11, Vol.8 (54), p.92604-92614
Hauptverfasser: Li, Yingjun, Bao, Chengzhen, Gu, Simeng, Ye, Ding, Jing, Fangyuan, Fan, Chunhong, Jin, Mingjuan, Chen, Kun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The metastasis-associated lung adenocarcinoma transcript 1 ( ), a well-known long non-coding RNA, is involved in pathogenesis and progress of multiple tumors. However, no study has been performed to investigate the relationship between the genetic variants in promoter region of and colorectal cancer risk. In this study, we conducted a two-stage case-control study to evaluate whether genetic variants were associated with colorectal cancer risk. We identified that a single nucleotide polymorphism (SNP) rs1194338 was significantly associated with the decreased colorectal cancer risk with an odds ratio (OR) of 0.70 [95% confidence interval (CI) = 0.49-0.99] in the combined stage. The subsequently stratified analyses showed that the protective effect of rs1194338 was more pronounced in several subgroups. Furthermore, gene expression profiling analysis revealed overexpression of mRNA in colorectal cancer tissue compared with normal controls. Confirmation studies with large sample size and further mechanistic investigations into the function of and its genetic variants are warranted to advance our understanding of their roles in colorectal carcinogenesis, and to aid in the development of novel and targeted therapeutic strategies.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.21507